Skip to main content

Elena de Sena Fernández

I am a molecular biologist with a strong background in developmental biology and +5 years of experience in research. I am currently working as a project manager in the Liver, Metabolism and Infections group in the Liver Center at VHIR. I am involved in managing the group's role in the european project EU-PEARL as well as looking an applying for national and international funding opportunitites. I am passionate about innovation and helping patients.

Institutions of which they are part

Administration and Management
Liver Diseases
Vall Hebron Institut de Recerca

Elena de Sena Fernández

Institutions of which they are part

Administration and Management
Liver Diseases
Vall Hebron Institut de Recerca

I am a molecular biologist with a strong background in developmental biology and +5 years of experience in research. I am currently working as a project manager in the Liver, Metabolism and Infections group in the Liver Center at VHIR. I am involved in managing the group's role in the european project EU-PEARL as well as looking an applying for national and international funding opportunitites. I am passionate about innovation and helping patients.

2022 - Present: Project Manager WP6 EU-PEARL (VHIR, Barcelona)
2018-2019: Postdoctoral Fellow (Ichan School of Medicine at Mount Sinai, New York)
2014 - 2018: PhD Student (Institut Curie, Orsay)

Projects

Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR).

IP: Meritxell Ventura Cots
Collaborators: Immaculada Raurell Saborit, Juan Manuel Pericàs Pulido, Laura Puente Ramo, Elena de Sena Fernández, Ares Aurora Villagrasa Vilella, Juan Bañares Sanchez, Jesus Manuel Rivera Esteban
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI22/01770
Duration: 01/01/2023 - 31/12/2025

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Victor Manuel Vargas Blasco, Maria Buti Ferret, Montserrat Gomez Perez, Torrens Buscató, Maria Margarita, Judit Vico Romero, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Elena de Sena Fernández, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, Jesus Manuel Rivera Esteban, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano, Cesar Jimenez Hernandez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

EU Patient- cEntric clinicAl tRial pLatform - EU PEARL.

IP: Joan Genescà Ferrer
Collaborators: Santiago Pérez Hoyos, Anna Sanjuan Viaplana, Xavier Cañas Perea, Juan Espinosa Pereiro, Juan Manuel Pericàs Pulido, José Antonio Ramos Quiroga, Israel Molina Romero, Alex Sánchez Pla, Inmaculada Fuentes Camps, Elena de Sena Fernández, Adrián Sánchez Montalvá, Pol Ibañez Jimenez, Olga Sánchez- Maroto Carrizo, Gara Arteaga Henriquez, Jesus Manuel Rivera Esteban, Sergio Gabriel Muñoz Martínez, Navarro Villarreal, Clara, Janna Anthonina Slabbekoorn, Albert Barberà LLuis
Funding agency: The Innovative Medicines Initiative
Funding: 1987375
Reference: EU-PEARL_H2020_IMI2-2018
Duration: 01/11/2019 - 30/04/2023

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Mireia  Beltran  Porres

Mireia Beltran Porres

Growth and Development
Read more
Carina Lera Asensio

Carina Lera Asensio

Research technician
Transfusional Medicine
Read more
Pere Canals Canals

Pere Canals Canals

Predoctoral researcher
Stroke research
Read more
Ester Sanchez Gavilan

Ester Sanchez Gavilan

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.